In a statement to PharmaTimes World News, AstraZeneca confirmed that it is part of the DoJ and SEC investigation into adherence with the FCPA, and that is is "co-operating with inquiries". However, the company added that it did not think it is appropriate "to comment at this time on matters that are the subject of the DOJ and SEC inquiries.”A spokesperson for GSK told PharmaTimes World News that it indeed received a letter relating to the investigation back in April, but stressed that in this particular instance, and from a GSK perspective, the enquiries are very much at a preliminary stage, whereas other drug companies already have ongoing interactions with the DoJ and SEC. Merck also disclosed that it has received inquiry letters in relation to activities in a number of countries in a recent quarterly SEC filing.
via pharmatimes.com
No comments:
Post a Comment